Molecular Medicine
Tri-Conference Plenary Session

The Molecular Medicine Tri-Conference celebrates its 25th anniversary in February 2018. Tri-Con originally started in the mid-1990s as three separate, back-to back conferences during the Human Genome Project, and stretched over 7 days: The Human Genome Project: Commercial Implications meeting, The Genetic Screening and Diagnosis of Human Diseases meeting, and The Genomic Partnering Forum. These meetings merged and over the years, other programs were added - but the term 'Tri-Con' has stuck.

Tri-Con has been and will continue to be a platform in recognizing the potential for new technologies and research in molecular medicine, diagnostics, drug discovery, and drug development that have a pivotal role in mitigating disease, improving access to healthcare, and identifying transformative treatments.

In honor of Tri-Con's 25th anniversary, we assembled key individuals like Leroy Hood and David Haussler who have had a seminal role in the HGP, to provide unique perspectives of genomic medicine over the years and visions for the future. Their presentations and others in the plenary keynote program will inspire you to continue efforts in developing novel medicines, diagnostics, therapeutics, and approaches to gain a greater understanding of the underpinnings of cancer and advance personalized medicine. We plan for Tri-Con to celebrate its 50th anniversary in 2043, and perhaps you'll be a featured speaker?

Join approximately 1,000 of your colleagues in each of these plenary keynote presentations. These are the only times each day that bring all attendees from the 16 conference programs together in one room.


5:00 - 6:00 pm

5:00 Welcome Remarks

5:05 Plenary Keynote Introduction

Daniel Kagan, Ph.D., COO, Scientist

5:15 Plenary Keynote Presentation

Leroy HoodLeroy Hood, M.D., Ph.D., President and Co-founder, Institute for Systems Biology; Senior Vice President & Chief Science Officer, Providence St. Joseph Health 

Dr. Hood's outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: "If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information." 

Hood was involved in the development of six instruments critical for contemporary biology-namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, the ink jet printer for constructing DNA arrays and large scale synthesis of DNA and the nanostring instrument for the single molecule analysis of RNA (and later DNA). These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine.  He helped pioneer the human genome program-making it possible with the automated DNA sequencer. Under Hood's direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15. 

In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology (ISB), the first committed to systems approach to biology and disease. He has pioneered systems medicine in the years since ISB's founding and has argued for a healthcare that is predictive, preventive, personalized and participatory (P4). Hood has made many seminal discoveries in the fields of immunology, neurobiology, cancer biology and biotechnology and, most recently, has been a leader in the development of systems biology and its applications to cancer and neurodegenerative diseases, as well as pioneering technologies and strategies that bring systems biology to personalized medicine.  

Hood is now pioneering new approaches to P4 medicine and most recently, has embarked on creating a P4 pilot project on 108 well individuals, that is transforming healthcare and leading to a new healthcare discipline termed scientific wellness. 

In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies-the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale

Dr. Hood has also had a life-long interest in K-12 science education and ISB has been a leader in this area. 

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing


8:00 - 9:00 am

8:00 am Welcome Remarks

8:15 State of the Industry Report: Cancer Research

 Sara_RedcliffeSara Radcliffe, President & CEO, California Life Sciences Association 

Sara Radcliffe was appointed the president and CEO of the California Life Sciences Association (CLSA) in December 2014. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA research. In addition, she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College. 

8:30 Plenary Keynote Presentation

9:00 Refreshment Break in the Exhibit Hall with Poster Viewing


8:00 - 10:00 am

8:00 Welcome Remarks

Diagnostics World Early Innovator Award logo8:05 Diagnostics World Early Innovator Award Program

8:15 Plenary Keynote Presentation

 David_HausslerDavid Haussler, Ph.D., Distinguished Professor and Scientific Director, UC Santa Cruz Genomics Institute, University of California, Santa Cruz 

David Haussler develops new statistical and algorithmic methods to explore the molecular function, evolution, and disease process in the human genome, integrating comparative and high-throughput genomics data to study gene structure, function, and regulation. He is credited with pioneering the use in genomics of hidden Markov models (HMMs), stochastic context-free grammars, and discriminative kernel methods. As a collaborator on the international Human Genome Project, his team posted the first publicly available computational assembly of the human genome sequence on the Internet on July 7, 2000. His team subsequently developed the UCSC Genome Browser, a web-based tool that is used extensively in biomedical research and serves, along with the Ensembl platform, virtually all large-scale vertebrate genomics projects, including NHGRI's ENCODE project, the 1000 Genomes Project, and NCI's TCGA. He built the CGHub database to hold NCI's cancer genome data and is a co-founder and organizing member of the Global Alliance for Genomics and Health (GA4GH), a coalition of the top research, health care, and disease advocacy organizations that have taken the first steps to standardize and enable secure sharing of genomic and clinical data. Haussler received his Ph.D. in Computer Science from the University of Colorado, Boulder. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and a fellow of AAAS and AAAI. He has won a number of awards, including the 2014 Dan David Prize, in the Future category, 2011 Weldon Memorial prize for application of mathematics and statistics to biology, 2009 ASHG Curt Stern Award in Human Genetics, the 2008 Senior Scientist Accomplishment Award from the International Society for Computational Biology, the 2006 Dickson Prize for Science from Carnegie Mellon University, and the 2003 ACM/ AAAI Allen Newell Award in Artificial Intelligence. 

8:45 Plenary Session Panel: Emerging Technologies and Industry Perspectives

This panel session will feature a series of presentations on emerging and hot technologies in molecular medicine. Each speaker will have 7 minutes at the podium. After all speakers have presented, there will be a moderated Q&A with attendees. The presentations are not meant to be a corporate or specific product pitch. Each speaker will focus on a technology and solution framed around a motivational clinical problem and how their particular company/organization is solving it.


Kristin Ciriello Pothier, Global Head of Life Sciences, Parthenon-EY

Scott Palmer, Senior Vice President and Head of Precision Medicine, Parthenon-EY


Dick Rubin, Vice President, Sales & Marketing, Business Development, XimedicaDx (formerly Accel Biotech)
Christopher Mueller, Ph.D., President & CTO, Lab7 Systems
Florian Bell, Senior Member, Technical Staff, Sensor System Integration, Qorvo
Tim Wesselman, CEO, OnRamp Bioinformatics Inc
Speaker to be Announced, Nanostring
Speaker to be Announced, Biocartis 
Speaker to be Announced, iSpecimen 


10:00 Refreshment Break and Poster Competition Winner Announced in the Exhibit Hall 

* 活動內容有可能不事先告知作更動及調整。

Choose your language


Premier Sponsors

Beckman Coulter Life Sciences 


Boston Healthcare


Clarivate Analytics



Menarini Silicon Biosystems









 Streck new brand

View All Sponsors